Gastroenterology: Beware of JAK inhibitor treatment leading to an increased risk of shingles in patients

Janus kinase inhibitors (Jaks) have been approved for the treatment of inflammatory bowel disease and a variety of other immunomediated diseasesThe treatment of ulcerative colitis is effective, but there are also safety issuesRecently, the researchers conducted a systematic review and meta-analysis to examine the safety of Tofadinib, Upatinib, and Barricktinib, as well as Barricktinib, in patients with rheumatoid arthritis, inflammatory bowel disease, psoriasis, or strong scoliosisresearchers collected data from 1990 to 2019, the main endpoints of the study were the adverse event rate and the rate of severe adverse events of JAK inhibitors, and also assessed the incidence of serious infections of JAK inhibitors, shingles infections, non-melanoma skin cancer, other malignant tumors, major cardiovascular events, venous thrombosis and mortalitya total of 973 literatures, including 66,159 patients with immunorelated diseases treated with JAK inhibitors, two-thirds of which were randomized controlledEvery 100 patients had 42.65 adverse events per year, 9.88 serious adverse events, and the incidence of severe infection, shingles infection, malignant tumor and major cardiovascular events was 2.81, 2.67, 0.89 and 0.48, respectivelyThe use of JAK inhibitors did not increase patient mortality (0.72) compared to placeboand and active controlsMeta-analysis showed that JAK inhibitors led to an increased risk of shingles in patients (1.57)studies have found a significant increase in the risk of shingles in patients with immunorelated diseases treated with JAK inhibitors